TRCT
LYEL icon

Tower Research Capital (TRC)’s Lyell Immunopharma LYEL Stock Holding History

Tower Research Capital (TRC)’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2K Buy
1,364
+63
+5% +$1.14K ﹤0.01% 3599
2026
Q1 		$26.1K Buy
1,301
+107
+9% +$2.5K ﹤0.01% 3289
2025
Q4 		$36.8K Sell
1,194
-664
-36% -$14.9K ﹤0.01% 2660
2025
Q3 		$30.2K Sell
1,858
-245
-12% -$2.8K ﹤0.01% 2925
2025
Q2 		$18.6K Buy
2,103
+890
+73% +$8.11K ﹤0.01% 3726
2025
Q1 		$13.1K Buy
1,213
+238
+24% +$2.92K ﹤0.01% 3401
2024
Q4 		$12.5K Buy
975
+562
+136% +$11.1K ﹤0.01% 3613
2024
Q3 		$11.4K Sell
413
-830
-67% -$24.4K ﹤0.01% 3667
2024
Q2 		$36K Buy
1,243
+1,042
+518% +$49.6K ﹤0.01% 3351
2024
Q1 		$8.95K Sell
201
-1,451
-88% -$62.1K ﹤0.01% 3925
2023
Q4 		$64.1K Buy
1,652
+193
+13% +$6.95K ﹤0.01% 2966
2023
Q3 		$42.9K Buy
1,459
+1,275
+693% +$60.5K ﹤0.01% 2682
2023
Q2 		$11.7K Sell
184
-350
-66% -$19.4K ﹤0.01% 3948
2023
Q1 		$25K Buy
534
+382
+251% +$20.4K ﹤0.01% 3207
2022
Q4 		$10K Sell
152
-275
-64% -$27.3K ﹤0.01% 4030
2022
Q3 		$63K Buy
427
+31
+8% +$4.2K ﹤0.01% 2957
2022
Q2 		$51K Sell
396
-37
-9% -$3.78K ﹤0.01% 2861
2022
Q1 		$44K Sell
433
-9
-2% -$1.09K ﹤0.01% 2834
2021
Q4 		$68K Buy
442
+318
+256% +$70.9K ﹤0.01% 2516
2021
Q3 		$37K Buy
+124
New +$37.2K ﹤0.01% 3199

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Tower Research Capital (TRC)'s LYEL Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Lyell Immunopharma (LYEL) stake by 4.8% in Q2 2026, buying an estimated $1.14K and bringing the position to 1,364 shares worth $19.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3599.

Tower Research Capital (TRC) first reported a position in LYEL in Q3 2021 and has held it in 20 quarters since. The position peaked at $68K in Q4 2021. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Tower Research Capital (TRC) held 1,364 shares of Lyell Immunopharma worth $19.2K as of Q2 2026.
  • Tower Research Capital (TRC) bought 63 Lyell Immunopharma shares in Q2 2026, an estimated $1.14K.
  • Lyell Immunopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3599 holding.
  • Tower Research Capital (TRC) first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Lyell Immunopharma position peaked at $68K in Q4 2021.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.